Carlyle Group, which sold its nine-year-old investment in Claris Lifesciences Ltd last year, is readying a bid for the Indian company’s injectable drugs business, according to two sources familiar with the development.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
